Application of somatostatin in mild acute pancreatitis

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200056770

Enrollment

Unknown

Registered

2022-02-15

Start date

2022-03-03

Completion date

Unknown

Last updated

2023-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute pancreatitis

Interventions

Control group :somatostatin

observation group:placebo

Eligibility

Sex/Gender

All

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: ? Have abdominal pain, fever, nausea and vomiting and other clinical symptoms; ? Amylase and lipase were more than 3ULN; (3) Imaging examination must confirm the diagnosis, and CT score is above GRADE C;BISAP score & gt;= 3 points; ? The onset to the hospital within 24 hours. ? The age is 20-50 ? No other underlying diseases ? No complicated organ failure

Exclusion criteria

Exclusion criteria: ? There were allergic reactions to the drugs in this study; ? patients with liver and kidney dysfunction; ? Breast-feeding or pregnant women; ? Patients with biliary pancreatitis who need surgical treatment.

Design outcomes

Primary

Measure	Time frame
amylase;lipase;white blood cell;CRP;	—

Countries

China

Contacts

Public Contactzhang rongchun

376092701@qq.com15829395903

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026